Spotlight on Internal Medicine

Credits: 0.25 CME / CNE
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 4: Heavily Treatment-Experienced Patients
Chloe Orkin, MBBCH, MSc, FRCP
Postgraduate Institute for Medicine

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 4: Heavily Treatment-Experienced Patients

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
  • Review recent data on new and emerging ART regimens

Activity Description

As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Jonathan Schapiro, MD
Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
  • Review recent data on new and emerging ART regimens

Activity Description

As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Jonathan Schapiro, MD
Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

Internal Medicine Presentations

1 CME / CNE / CPE
Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

2.00 CME
The Academy for Continued Healthcare Learning
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Start

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC

Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC

Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO

Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at [email protected]

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC

Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC

Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO

Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at [email protected]

1.00 CME / MOC
Forefront Collaborative
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Novel Targeted Therapies in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Novel Targeted Therapies in the Treatment of Systemic Lupus Erythematosus

Start

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: May 21, 2021
Expires: May 21, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

  • Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
  • Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
  • Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Bevra H. Hahn, MD
Distinguished Professor of Medicine (Emeritus),
Division of Rheumatology
University of California, Los Angeles
Los Angeles, California


Lauren Irving
Patient Presenter

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
  • Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

  • Advisory Board: Janssen, GlaxoSmithKline
  • Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

  • Advisory Board: Janssen
  • Consulting Fee: Aurinia
  • Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME®: The UEMS-EACCME® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: May 21, 2021
Expires: May 21, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

  • Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
  • Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
  • Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Bevra H. Hahn, MD
Distinguished Professor of Medicine (Emeritus),
Division of Rheumatology
University of California, Los Angeles
Los Angeles, California


Lauren Irving
Patient Presenter

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
  • Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

  • Advisory Board: Janssen, GlaxoSmithKline
  • Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

  • Advisory Board: Janssen
  • Consulting Fee: Aurinia
  • Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME®: The UEMS-EACCME® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

1.00 CME
SHM (Society of Hospital Medicine)
Hospitalists Guide to COVID-19

Hospitalists Guide to COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

1.00 CME / CC
Vindico Medical Education
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Investigating the Role of New and Emerging Biologic Therapies

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Investigating the Role of New and Emerging Biologic Therapies

Start

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABOHNS Continuing Certification
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, immunologists, otolaryngologists, and other health care professionals involved in the management of patients with chronic rhinosinusitis with nasal polyps.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the underlying pathophysiology and differentiation of chronic rhinosinusitis with nasal polyps (CRSwNP).
  • Review the rationale for the use of biologic therapies, including appropriate use in patients with CRSwNP who have had an inadequate response to conventional treatments.
  • Evaluate the clinical trial data of new and emerging biologic therapies based on their mechanisms of action, safety, and efficacy for the treatment of patients with CRSwNP.

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a challenge for otolaryngologists, allergists, and immunologists alike. This disease recurs in up to 80% of patients after sinus surgery followed by medical treatment, and about 40% of patients may need at least one further surgery over the next 10 years. The pathogenesis of CRSwNP is elusive, and differentiating subtypes is challenging. Emerging biologic therapies hold promise in treating this debilitating condition. In this interactive educational activity, the pathogenesis and treatment of CRSwNP is discussed by expert clinicians.

Agenda

Underlying Immunopathology of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Whitney W. Stevens, MD, PhD, FAAAAI

Overview of Treatment of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Michael S. Blaiss, MD

A Look at the Clinical Evidence of New and Emerging Biologics
Joseph K. Han MD, FARS, FAAAAI

Activity Chair

Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Executive Medical Director, American College of Allergy, Asthma, and Immunology
Augusta, GA

Disclosure:
Consulting Fee: ALK, Covis, Merck, Pfizer, Sanofi/Regeneron

Faculty

Joseph K. Han MD, FARS, FAAAAI
Professor – Eastern Virginia Medical School
Norfolk, VA

Disclosure:
Consulting Fee: AstraZeneca, Genentech, GlaxoSmithKline, Intersect, Medtronic, OptiNose, Sanofi Genzyme

Whitney W. Stevens, MD, PhD, FAAAAI
Assistant Professor
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure:
Consulting Fee: Bristol Myers Squibb, Genentech, GlaxoSmithKline
Speakers Bureau: GlaxoSmithKline

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABOHNS Continuing Certification
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, immunologists, otolaryngologists, and other health care professionals involved in the management of patients with chronic rhinosinusitis with nasal polyps.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the underlying pathophysiology and differentiation of chronic rhinosinusitis with nasal polyps (CRSwNP).
  • Review the rationale for the use of biologic therapies, including appropriate use in patients with CRSwNP who have had an inadequate response to conventional treatments.
  • Evaluate the clinical trial data of new and emerging biologic therapies based on their mechanisms of action, safety, and efficacy for the treatment of patients with CRSwNP.

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a challenge for otolaryngologists, allergists, and immunologists alike. This disease recurs in up to 80% of patients after sinus surgery followed by medical treatment, and about 40% of patients may need at least one further surgery over the next 10 years. The pathogenesis of CRSwNP is elusive, and differentiating subtypes is challenging. Emerging biologic therapies hold promise in treating this debilitating condition. In this interactive educational activity, the pathogenesis and treatment of CRSwNP is discussed by expert clinicians.

Agenda

Underlying Immunopathology of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Whitney W. Stevens, MD, PhD, FAAAAI

Overview of Treatment of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Michael S. Blaiss, MD

A Look at the Clinical Evidence of New and Emerging Biologics
Joseph K. Han MD, FARS, FAAAAI

Activity Chair

Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Executive Medical Director, American College of Allergy, Asthma, and Immunology
Augusta, GA

Disclosure:
Consulting Fee: ALK, Covis, Merck, Pfizer, Sanofi/Regeneron

Faculty

Joseph K. Han MD, FARS, FAAAAI
Professor – Eastern Virginia Medical School
Norfolk, VA

Disclosure:
Consulting Fee: AstraZeneca, Genentech, GlaxoSmithKline, Intersect, Medtronic, OptiNose, Sanofi Genzyme

Whitney W. Stevens, MD, PhD, FAAAAI
Assistant Professor
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure:
Consulting Fee: Bristol Myers Squibb, Genentech, GlaxoSmithKline
Speakers Bureau: GlaxoSmithKline

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

1.00 CME / MOC
Forefront Collaborative
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus

Start

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

0.50 CME
Vindico Medical Education
Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

0.50 CME / MOC
Vindico Medical Education
Improving Cardiovascular Outcomes by Decreasing Residual Risk: Take the Wheel of Knowledge Challenge

Improving Cardiovascular Outcomes by Decreasing Residual Risk: Take the Wheel of Knowledge Challenge

Start

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/
ABIM MOC
Released: February 12, 2021
Expires: February 11, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists, internists, and other health care professionals involved in the management of patients with, or at risk for cardiovascular disease.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Utilize appropriate methods to assess residual risk in patients with controlled low-density lipoprotein cholesterol (LDL-C).
  • Evaluate the latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention.
  • Identify patients who may benefit from additional treatment to reduce cardiovascular risk despite the management of other risk factors and manage them accordingly.

Activity Description

Cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States, despite therapeutic advances. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), has been a major focus of preventive therapy. Notably, high triglyceride levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. Increasingly, cardiologists have recognized that patients with hypertriglyceridemia experience residual CVD risk and adverse cardiovascular events. Cardiologists and other health care professionals are now rethinking their treatment regimens in light of new findings from cardiovascular outcomes trials. In addition, new evidence continues to emerge regarding cardioprotective mechanisms that underlie newer medications for CVD risk reduction. In this Wheel of Knowledge Challenge, an interactive quiz of knowledge and confidence, your knowledge will be tested on the latest clinical developments and management strategies for patients with, or at risk for, cardiovascular disease. This medical education program will address methods for assessing residual risk in patients with controlled LDL-C. The latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention are also considered, along with methods for identifying patients who may benefit from additional treatment to reduce cardiovascular risk.

Faculty

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, SC


Disclosure:

Consulting Fee: Amgen, Esperion

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, February 12, 2021 to February 11, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/
ABIM MOC
Released: February 12, 2021
Expires: February 11, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists, internists, and other health care professionals involved in the management of patients with, or at risk for cardiovascular disease.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Utilize appropriate methods to assess residual risk in patients with controlled low-density lipoprotein cholesterol (LDL-C).
  • Evaluate the latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention.
  • Identify patients who may benefit from additional treatment to reduce cardiovascular risk despite the management of other risk factors and manage them accordingly.

Activity Description

Cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States, despite therapeutic advances. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), has been a major focus of preventive therapy. Notably, high triglyceride levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. Increasingly, cardiologists have recognized that patients with hypertriglyceridemia experience residual CVD risk and adverse cardiovascular events. Cardiologists and other health care professionals are now rethinking their treatment regimens in light of new findings from cardiovascular outcomes trials. In addition, new evidence continues to emerge regarding cardioprotective mechanisms that underlie newer medications for CVD risk reduction. In this Wheel of Knowledge Challenge, an interactive quiz of knowledge and confidence, your knowledge will be tested on the latest clinical developments and management strategies for patients with, or at risk for, cardiovascular disease. This medical education program will address methods for assessing residual risk in patients with controlled LDL-C. The latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention are also considered, along with methods for identifying patients who may benefit from additional treatment to reduce cardiovascular risk.

Faculty

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, SC


Disclosure:

Consulting Fee: Amgen, Esperion

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, February 12, 2021 to February 11, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

2 CME / CNE
Postgraduate Institute for Medicine
What's New in Systemic Lupus Erythematosus? Unlocking Novel Paths to Patient Care

What's New in Systemic Lupus Erythematosus? Unlocking Novel Paths to Patient Care

Start

Activity Details

Free CME/CNE
2.0 AMA PRA Category 1 Credit(s)
2.0 Contact Hour(s)
Released: January 30, 2021
Expires: January 30, 2022
120 minutes to complete

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is intended for rheumatologists and other specialists involved in the management of patients with systemic lupus erythematosus (SLE).

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe SLE pathophysiology with a focus on novel treatment targets
  • Evaluate patients with SLE using evidence-based classification criteria and measures of disease activity
  • Discuss new clinical trial data and regulatory status for current and emerging targeted therapies in moderate-to-severe SLE
  • Manage patients with moderate-to-severe SLE based on a treat-to-target approach, evolving clinical evidence, unresolved symptoms, and patient preferences

Activity Description

Despite improved understanding of pathophysiologic mechanisms, additional assessment strategies, and hope for more available treatments, specialists face challenges in managing the diverse manifestations of, and patient populations with, SLE. During this Engaging the Patient™ enduring activity, a panel of 3 experts in SLE share interpretive insights on SLE pathophysiology, diagnosis, the use of classification criteria and measures of disease activity, and recent clinical trial data for newer targeted therapies. This forward-looking CME program aims to capture expert interpretations of existing and evolving evidence to help rheumatologists provide care that minimizes recurrent disease activity flares and cumulative organ damage that are key factors in long-term outcomes.

Agenda

  • How Do We Evaluate Patients with Suspected SLE?
  • Comprehensive Treatment of SLE: Where are We Now?
  • Insights into SLE Pathophysiology
  • Linking Pathophysiology to Targets for Drug Development
  • Patient Goals, Treat-to-Target, and Treatment Success
  • Faculty Closing Comments
  • Ask the Experts Q&A Session

Faculty

Richard A. Furie, MD
Chief of Rheumatology
Northwell Health
Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Great Neck, New York

Consulting Fees:
Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo Company, Limited, Eli Lilly and Company, EMD Serono, Equillium, Inc., Galapagos NV, Genentech, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., MorphoSys AG, Novartis International AG, Reistone Biopharma, Sanofi S.A., Takeda Pharmaceutical Company Limited, UCB; Contracted Research/Investigator: Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, EMD Serono, Equillium, Inc., Genentech, GlaxoSmithKline plc., Kezar Life Sciences, Inc., Nektar Therapeutics, Takeda Pharmaceutical Company Limited, UCB; Other (Committee Member): Lupus Research Alliance, The Lupus Academy


Elena M. Massarotti, MD
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Lupus Trials
Division of Rheumatology
Vice Chair of Clinical Affairs
Department of Medicine
Brigham and Women's Hospital
Boston, Massachusetts

Royalties:
UpToDate; Consulting Fees: Amgen Inc., EMD Serono, Kezar Life Sciences, Inc.; Contracted Research: Bristol Myers Squibb, Sanofi S.A.


Eric Morand, MBBS (Hons), PhD, FRACP
Professor of Medicine
Department of Medicine
Head, Rheumatic Disease Group
Monash Centre for Inflammatory Diseases
Monash University (Australia)
Melbourne, Australia

Consulting Fees:
AbbVie, Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, GlaxoSmithKline plc., UCB; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents: Sanofi, Novartis; Contracted Research: AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Janssen Pharmaceuticals, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

PIM designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

In order to receive credit, participants must complete the preactivity questionnaire, posttest, and program evaluation. Participants must also score a 75% on the posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com.

Integritas Contact Information
For all other questions regarding this activity, please contact Christa Master with Integritas Communications via email at [email protected]

Activity Details

Free CME/CNE
2.0 AMA PRA Category 1 Credit(s)
2.0 Contact Hour(s)
Released: January 30, 2021
Expires: January 30, 2022
120 minutes to complete

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is intended for rheumatologists and other specialists involved in the management of patients with systemic lupus erythematosus (SLE).

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe SLE pathophysiology with a focus on novel treatment targets
  • Evaluate patients with SLE using evidence-based classification criteria and measures of disease activity
  • Discuss new clinical trial data and regulatory status for current and emerging targeted therapies in moderate-to-severe SLE
  • Manage patients with moderate-to-severe SLE based on a treat-to-target approach, evolving clinical evidence, unresolved symptoms, and patient preferences

Activity Description

Despite improved understanding of pathophysiologic mechanisms, additional assessment strategies, and hope for more available treatments, specialists face challenges in managing the diverse manifestations of, and patient populations with, SLE. During this Engaging the Patient™ enduring activity, a panel of 3 experts in SLE share interpretive insights on SLE pathophysiology, diagnosis, the use of classification criteria and measures of disease activity, and recent clinical trial data for newer targeted therapies. This forward-looking CME program aims to capture expert interpretations of existing and evolving evidence to help rheumatologists provide care that minimizes recurrent disease activity flares and cumulative organ damage that are key factors in long-term outcomes.

Agenda

  • How Do We Evaluate Patients with Suspected SLE?
  • Comprehensive Treatment of SLE: Where are We Now?
  • Insights into SLE Pathophysiology
  • Linking Pathophysiology to Targets for Drug Development
  • Patient Goals, Treat-to-Target, and Treatment Success
  • Faculty Closing Comments
  • Ask the Experts Q&A Session

Faculty

Richard A. Furie, MD
Chief of Rheumatology
Northwell Health
Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Great Neck, New York

Consulting Fees:
Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo Company, Limited, Eli Lilly and Company, EMD Serono, Equillium, Inc., Galapagos NV, Genentech, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., MorphoSys AG, Novartis International AG, Reistone Biopharma, Sanofi S.A., Takeda Pharmaceutical Company Limited, UCB; Contracted Research/Investigator: Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, EMD Serono, Equillium, Inc., Genentech, GlaxoSmithKline plc., Kezar Life Sciences, Inc., Nektar Therapeutics, Takeda Pharmaceutical Company Limited, UCB; Other (Committee Member): Lupus Research Alliance, The Lupus Academy


Elena M. Massarotti, MD
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Lupus Trials
Division of Rheumatology
Vice Chair of Clinical Affairs
Department of Medicine
Brigham and Women's Hospital
Boston, Massachusetts

Royalties:
UpToDate; Consulting Fees: Amgen Inc., EMD Serono, Kezar Life Sciences, Inc.; Contracted Research: Bristol Myers Squibb, Sanofi S.A.


Eric Morand, MBBS (Hons), PhD, FRACP
Professor of Medicine
Department of Medicine
Head, Rheumatic Disease Group
Monash Centre for Inflammatory Diseases
Monash University (Australia)
Melbourne, Australia

Consulting Fees:
AbbVie, Amgen Inc., AstraZeneca, Biogen, Bristol Myers Squibb, GlaxoSmithKline plc., UCB; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents: Sanofi, Novartis; Contracted Research: AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Janssen Pharmaceuticals, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

PIM designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

In order to receive credit, participants must complete the preactivity questionnaire, posttest, and program evaluation. Participants must also score a 75% on the posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com.

Integritas Contact Information
For all other questions regarding this activity, please contact Christa Master with Integritas Communications via email at [email protected]

0.50 CME
Vindico Medical Education
Calcitropes, Myotropes, and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF

Calcitropes, Myotropes, and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 27, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with heart failure with reduced ejection fraction (HFrEF).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the benefits and pitfalls of traditional inotropic agents and their impact on long-term outcomes in the treatment of HFrEF.
  • Evaluate new terminology with mechanistic nomenclature to foster effective communication and highlight novel therapeutic agents to improve myocardial contractility and function.
  • Assess the unique mechanisms of action of cardiac myotropes and clinical evidence regarding their safety and efficacy in the treatment of HFrEF.

Activity Description

Reductions in myocardial contractile function and increases in cardiac wall stress can trigger multiple interrelated compensatory mechanisms, including neurohormonal activation and ventricular remodeling. These result in increased myocardial oxygen demand and reduced contractile efficiency, promoting additional myocardial injury and cardiomyocyte death. These effects perpetuate a negative feedback cycle that results in symptomatic heart failure with a reduced ejection fraction (HFrEF) and, eventually, death.

Multiple lifesaving therapies, including angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mineralocorticoid antagonists; beta blockers; and, most recently, dual-acting angiotensin receptor-neprilysin inhibitors, have been developed to address the neurohormonal activation in HFrEF. However, these therapies do not directly address the central driver in the pathogenesis of HFrEF—decreased myocardial contractility—resulting in decrease systolic function. The use of conventional inotropic agents may increase morbidity as well as mortality and are associated with a higher risk of ventricular arrhythmia, atrial fibrillation, hypotension, induced myocardial ischemia, increased myocardial oxygen consumption, and direct myocyte toxicity due to an intracellular calcium overload.

Pharmacologic agents that improve myocardial performance can be classified as calcitropes that alter intracellular calcium concentrations, myotropes that affect the molecular motor and scaffolding, and mitotropes that influence the myocardial energetics. In this educational activity, faculty will discuss the latest data regarding newer agents in development that can directly enhance myocardial contractility, without increasing cardiac workload or oxygen consumption.

Agenda

Matters of the Heart: Unmet Needs in Heart Failure With Reduced Ejection Fraction (HFrEF)

Emerging HFrEF Therapies: A Look at the Clinical Evidence

Activity Chair

John R. Teerlink, MD, FACC, FAHA, FESC, FHFA, FHFSA, FRCP(UK)
Professor of Medicine, University of California San Francisco
Director, Heart Failure Program
Director, Echocardiography
San Francisco VA Medical Center
San Francisco, CA

Consulting Fee: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis
Contracted Research: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis

Faculty

Mitchell A. Psotka, MD, PhD, FACC, FHFSA
Director, Infiltrative Cardiomyopathy Center
Associate Director, Heart Failure Research
Inova Heart and Vascular Institute
Falls Church, VA

Consulting Fee: Amgen, Cytokinetics, Windtree

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Cytokinetics, Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 27, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with heart failure with reduced ejection fraction (HFrEF).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the benefits and pitfalls of traditional inotropic agents and their impact on long-term outcomes in the treatment of HFrEF.
  • Evaluate new terminology with mechanistic nomenclature to foster effective communication and highlight novel therapeutic agents to improve myocardial contractility and function.
  • Assess the unique mechanisms of action of cardiac myotropes and clinical evidence regarding their safety and efficacy in the treatment of HFrEF.

Activity Description

Reductions in myocardial contractile function and increases in cardiac wall stress can trigger multiple interrelated compensatory mechanisms, including neurohormonal activation and ventricular remodeling. These result in increased myocardial oxygen demand and reduced contractile efficiency, promoting additional myocardial injury and cardiomyocyte death. These effects perpetuate a negative feedback cycle that results in symptomatic heart failure with a reduced ejection fraction (HFrEF) and, eventually, death.

Multiple lifesaving therapies, including angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mineralocorticoid antagonists; beta blockers; and, most recently, dual-acting angiotensin receptor-neprilysin inhibitors, have been developed to address the neurohormonal activation in HFrEF. However, these therapies do not directly address the central driver in the pathogenesis of HFrEF—decreased myocardial contractility—resulting in decrease systolic function. The use of conventional inotropic agents may increase morbidity as well as mortality and are associated with a higher risk of ventricular arrhythmia, atrial fibrillation, hypotension, induced myocardial ischemia, increased myocardial oxygen consumption, and direct myocyte toxicity due to an intracellular calcium overload.

Pharmacologic agents that improve myocardial performance can be classified as calcitropes that alter intracellular calcium concentrations, myotropes that affect the molecular motor and scaffolding, and mitotropes that influence the myocardial energetics. In this educational activity, faculty will discuss the latest data regarding newer agents in development that can directly enhance myocardial contractility, without increasing cardiac workload or oxygen consumption.

Agenda

Matters of the Heart: Unmet Needs in Heart Failure With Reduced Ejection Fraction (HFrEF)

Emerging HFrEF Therapies: A Look at the Clinical Evidence

Activity Chair

John R. Teerlink, MD, FACC, FAHA, FESC, FHFA, FHFSA, FRCP(UK)
Professor of Medicine, University of California San Francisco
Director, Heart Failure Program
Director, Echocardiography
San Francisco VA Medical Center
San Francisco, CA

Consulting Fee: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis
Contracted Research: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis

Faculty

Mitchell A. Psotka, MD, PhD, FACC, FHFSA
Director, Infiltrative Cardiomyopathy Center
Associate Director, Heart Failure Research
Inova Heart and Vascular Institute
Falls Church, VA

Consulting Fee: Amgen, Cytokinetics, Windtree

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Cytokinetics, Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

Pages